| 慈轶宏,徐天朝,李冬冬,王 洋,王一同.舒肝解郁胶囊联合阿戈美拉汀对抑郁症患者血清单胺类神经递质和神经功能相关因子的影响[J].,2022,(12):2298-2302 |
| 舒肝解郁胶囊联合阿戈美拉汀对抑郁症患者血清单胺类神经递质和神经功能相关因子的影响 |
| Effects of Shugan Jieyu Capsule Combined with Agomelatine on Serum Monoamine Neurotransmitters and Nerve Function Related Factors in Patients with Depression |
| 投稿时间：2021-12-08 修订日期：2021-12-31 |
| DOI：10.13241/j.cnki.pmb.2022.12.020 |
| 中文关键词: 舒肝解郁胶囊 阿戈美拉汀 抑郁症 单胺类神经递质 神经功能 |
| 英文关键词: Shugan Jieyu capsule Agomelatine Depression Monoamine neurotransmitters Nerve function |
| 基金项目:辽宁省自然科学基金指导计划项目（20170540961）；军队后勤科研重点课题（BLB19J012） |
|
| 摘要点击次数: 831 |
| 全文下载次数: 446 |
| 中文摘要: |
| 摘要 目的：观察舒肝解郁胶囊联合阿戈美拉汀治疗抑郁症的疗效及对血清单胺类神经递质和神经功能相关因子的影响。方法：纳入我院2017年5月~2020年5月接诊的120例抑郁症患者，经双色球随机分组法将患者分为对照组和观察组，各为60例。对照组患者予以阿戈美拉汀治疗，观察组患者予以舒肝解郁胶囊联合阿戈美拉汀治疗。比较两组疗效、血清单胺类神经递质、神经功能相关因子、抑郁焦虑评分及不良反应发生率。结果：观察组的临床总有效率为93.33%（56/60），高于对照组的73.33%（44/60）（P<0.05）。两组治疗6周后汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）评分较治疗前降低，且观察组较对照组低（P<0.05）。两组治疗6周后多巴胺（DA）、去甲肾上腺素（NE）、5-羟色胺（5-HT）水平较治疗前升高，且观察组高于对照组（P<0.05）。两组治疗6周后S100?茁、髓磷脂碱性蛋白（MBP）、神经元特异性烯醇化酶（NSE）水平较治疗前降低，且观察组低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：舒肝解郁胶囊联合阿戈美拉汀治疗抑郁症，疗效显著，可有效调节血清单胺类神经递质和神经功能，改善抑郁症状，且安全可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy of Shugan Jieyu capsule combined with agomelatine in the treatment of depression and its effect on serum monoamine neurotransmitters and nerve function related factors. Methods: 120 patients with depression who were received in our hospital from May 2017 to May 2020 were included. The patients were divided into control group and observation group by two color ball random grouping method, with 60 cases in each group. The patients in the control group were treated with agomelatine, and the patients in the observation group were treated with Shugan Jieyu capsule combined with agomelatine. The efficacy, serum monoamine neurotransmitters, nerve function related factors, depression and anxiety score and the incidence of adverse reactions were compared between the two groups. Results: The total clinical effective rate in the observation group was 93.33% (56/60), which was higher than 73.33% (44/60) in the control group (P<0.05). 6 weeks after treatment, the scores of Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) in both groups were lower than those before treatment, and the scores of observation group were lower than those of control group (P<0.05). 6 weeks after treatment, the levels of dopamine (DA), norepinephrine (NE) and serotonin (5-HT) in both groups were higher than those before treatment, and those in observation group were higher than those in control group (P<0.05). 6 weeks after treatment, the levels of S100β, myelin basic protein (MBP) and neuron specific enolase (NSE) in both groups were lower than those before treatment, and those in observation group were lower than those in control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Shugan Jieyu capsule combined with agomelatine is effective in the treatment of depression. It can effectively regulate serum monoamine neurotransmitters and neural function, improve depressive symptoms, and is safe and reliable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
